A Siemens commissioned study has identified the UK and Irish biopharmaceutical sector’s key areas for priority investment in digitalisation, with the challenges of time to market and making sense of large amounts of data running as a constant thread.
The independent research engaged 31 key players in the UK and Irish biopharmaceutical sector to discover key areas for business improvement. The study was conducted between late 2019 and early 2022, covering the period affected by the global pandemic. The key findings indicate that digital transformation in biopharmaceuticals is expected to pick up speed across…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
